In this video, Motley Fool health-care bureau chief Brenton Flynn takes a closer look at Dendreon (NAS: DNDN) , a company that has underperformed recently, to shareholders' chagrin. Brenton looked at the company's recent SEC filings and gives us a few interesting pieces of information about the company he gleaned from them. For one thing, the company had been sitting on some zero-cost antigen inventory, and benefiting from that wasn't being recognized as an expense. Second, the company made a sharp move by selling its royalty rights to Merck's (NYS: MRK) hepatitis C drug Victrelis last year for $125 million.
Dendreon's run over the past four years witnessed sub-$5 share prices skyrocket to 10-bagger status before tumbling all the way back down below $5, as its revolutionary prostate cancer vaccine Provenge became a lightning rod of debate. But where does that leave investors -- other than a bit nauseated from the roller-coaster ride? Our own David Williamson answers this question, and many more, inside our brand new premium research report on Dendreon. Inside, he details every key issue facing the company and outlines just how Dendreon intends to regain its former glory. The report also comes with a full year of analyst updates, so claim your copy of this exclusive report today by clicking here now.
The article What's Changed With Dendreon? originally appeared on Fool.com.
Brenton Flynn and Max Macaluso have no positions in the stocks mentioned above. The Motley Fool owns shares of Dendreon. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.